IMUX, US4525EP2001

Twelve analysts set a USD 35.43 target for Immunic stock

Published on 10/20/2026 at 20:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MarketBeat says institutions held 51.82 percent on October 9, 2026. Immunic stock costs EUR 6.62 on October 20, 2026 at 7:53 p.m. CEST.

Analyst target and reporting date

Twelve brokerages gave Immunic a Buy consensus and a USD 35.43 average 12-month target on October 9, 2026.
Institutions held 51.82 percent of Immunic stock on October 9, 2026.
Immunic stock was trading at EUR 6.62 at Lang & Schwarz on October 20, 2026 at 7:53 p.m. CEST.
Top-line Phase 3 data for vidofludimus calcium are expected by the end of 2026.

IMUX, US4525EP2001, Illustration mit AI erstellt.

Immunic stock (ISIN US4525EP2001) has a USD 35.43 average 12-month price target from twelve brokerages, while the company remains focused on late-stage multiple sclerosis trials. MarketBeat reported the Buy consensus and target on October 9, 2026. The stock was trading at EUR 6.62 at Lang & Schwarz on October 20, 2026 at 7:53 p.m. CEST.

Analysts remain divided

The average target was based on twelve brokerages, including seven Buy ratings, three Strong Buy ratings, one Hold rating and one Sell rating, according to MarketBeat. The target therefore masks a wide range of views rather than a single unified forecast.

Institutional investors held 51.82 percent of Immunic stock on October 9, 2026. That ownership figure gives the analyst consensus greater relevance for liquidity and positioning, but it does not remove the clinical risk attached to a late-stage biotechnology company.

Clinical milestones carry the valuation

Immunic is developing oral therapies for neurologic and autoimmune diseases. Its lead program, vidofludimus calcium, is in Phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, according to the company's investor-relations page.

The company reported quarterly earnings per share of minus USD 0.80 in the quarter reported on August 11, 2026, beating the consensus estimate of minus USD 1.16 by USD 0.36, MarketBeat reported. The result is a financial marker, while the 2026 clinical readouts remain the central company-specific milestone.

Valuation and upcoming milestones

Immunic had a market capitalization of USD 101.8 million and a price-to-earnings ratio of minus 1.55 as of October 20, 2026. Its 52-week trading range was USD 5.06 to USD 17.43, placing the latest Nasdaq quote at USD 7.46 on October 20, 2026 at 1:57 p.m. ET.

The investor-relations page identifies Nasdaq under ticker IMUX and says top-line data are expected by the end of 2026. The same page describes a further Phase 3 trial in progressive multiple sclerosis as expected later in 2026, keeping clinical execution ahead of reported earnings as the principal valuation variable.

Price and investor perspective

At EUR 6.62 in late trading at Lang & Schwarz, Immunic remains closer to its 52-week low of USD 5.06 than to its high of USD 17.43 when measured against the Nasdaq quotation. The different currencies prevent a direct percentage comparison, but the levels underline the gap between the market quotation and the USD 35.43 analyst average target.

The further course of trading is shown by the continuously updated real-time quote of Immunic stock.